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Abstract
Background: Prevention of Mother-to-Child HIV Transmission (PMTCT) is still the most effective intervention in
combating new HIV infections. In 2008, revised national PMTCT guidelines that incorporated new policies on HIV
counselling and testing, antiretroviral prophylaxis regimen and infant HIV diagnosis came into effect in Ethiopia. In
the present study we have examined trends in PMTCT service utilization and assessed the rate of MTCT in relation
to policy changes in the national PMTCT programme.
Methods: Reports from February 2004 to August 2009 were reviewed in 10 sub-cities in Addis Ababa, Ethiopia.
The data was collected from May to October 2009.
Results: The proportion of women who received HIV counselling and testing among new antenatal care attendees
increased from 50.7% (95% CI 50.2-51.2) in 2007 to 84.5% (95% CI 84.1-84.9) in 2009 following the shift to routine
opt-out testing. Nevertheless, in 2009 only 53.7% of the positive women and 40.7% of their infants received
antiretroviral prophylaxis. The HIV prevalence among antenatal attendees decreased significantly from 10.5% in
2004 to 4.6% in 2009 in parallel to the increased number of women being tested. The HIV positive women were
over 18 times (RR 18.5, p < 0.0001) more likely to be referred for treatment, care and support in 2009 than in 2004.
The proportion of partners tested for HIV decreased by 14% in 2009 compared to 2004, although the absolute
number was increasing year by year. Only 10.6% (95% CI 9.9-11.2) of the HIV positive women completed their
follow up to infant HIV testing. The cumulative probability of HIV infection among babies on single dose
nevirapine regimen who were tested at >=18 months was 15.0% (95% CI 9.8-22.1) in 2007, whereas it was 8.2%
(95% CI 5.55-11.97) among babies on Zidovudine regimen who were tested at >=45 days in 2009.
Conclusion: The paper demonstrates trends in PMTCT service utilization in relation to changing policy. There is marked
improvement in HIV counselling and testing service utilization, especially after the policy shift to routine opt-out testing.
However, despite policy changes, the ARV prophylaxis uptake, the loss to follow up and the partner testing have
remained unchanged across the years. This should be a matter of immediate concern and a topic for further research.
Background
Prevention of mother-to-child HIV transmission
(PMTCT) is still the most effective intervention in com-
bating new HIV infections [1]. When the possibility of
having an efficacious vaccine seems questionable, as
reported in a recent vaccine trial, holding on to PMTCT
programmes gives some hope [2]. PMTCT is a multifa-
ceted intervention. It is not just a way to stop vertical
transmission of HIV but also to provide access to treat-
ment, care and support for women who would other-
wise not get the chance to know their HIV status before
it is too late [1].
Despite its importance, a PMTCT programme often
suffers poor resource allocation that could threaten
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programme success [3]. Globally, the challenges in
PMTCT programme implementation combined with
ever changing scientific advances call for frequent revi-
sits of policies and strategies. In Ethiopia, the first
PMTCT guidelines were developed in 2001, incorporat-
ing early recommendations by the WHO on HIV coun-
selling and testing, ARV prophylaxis regimen, infant
feeding counselling, infant HIV diagnosis algorithm,
partner testing and referring HIV positive pregnant
women for treatment, care and support [4]. During the
recent years, the WHO has made several policy changes
to improve PMTCT programme performance. In 2004,
the HIV counselling and testing policy was shifted from
client initiated opt-in approach to routine opt-out
approach in order to improve women’s access to pre-
vention interventions and to contain HIV testing within
the standard of care for pregnant women [5]. In 2006,
the antiretroviral (ARV) prophylaxis regimen was chan-
ged from short course single dose NVP (sdNVP) to a
more efficacious multidrug zidovudine (ZDV) regimen
[1,6]. The infant feeding recommendation was also
revised in 2006, when exclusive breast feeding became
the preferred method for the first six months, plus com-
plementary feeding from six months. As alternative
feeding method, exclusive formula was recommended if
formula was acceptable, feasible, affordable, sustainable
and safe (AFASS) [7].
The national PMTCT guidelines were revised in 2007,
incorporating the policy changes made by the WHO
from 2004 to 2006, while retaining the early recommen-
dations on partner testing [6]. The revised guidelines
state that all pregnant women undergoing HIV counsel-
ling and testing should be advised to bring their partner
for HIV testing [6]. Partner testing and involvement in
PMTCT is intended to facilitate the women’s coping
with their test results, adherence to PMTCT recommen-
dations and to facilitate disclosure [8]. However, the
potentials of partner testing in PMTCT settings for the
prevention of horizontal transmission of HIV is often
neglected. Orne-Gliemann et al. described that the large
proportion of new HIV infections is occurring in conju-
gal relationship [9]. Studies from southern and eastern
Africa also reported that the prevalence of HIV sero-dis-
cordance is within the range of 36%-85% [3,10]. Preg-
nant women who were HIV negative in early pregnancy
could be at risk of acquiring new infection if they had a
positive partner at home, which in turn would increase
the risk of mother-to-child HIV transmission (MTCT).
In Ethiopia a Monitoring and Evaluation system for
HIV/AIDS (M&E) was first launched in 2003 [11]. The
system was established to support and strengthen evi-
dence based performance monitoring for HIV/AIDS
related interventions [4]. As part of the M&E system,
monthly PMTCT reports have been collected from dif-
ferent service outlets to evaluate the performance of the
national PMTCT programme at facility, sub-city and
region level since the launching of the programme.
However, despite the availability of comprehensive
PMTCT reports the impact of the programme has not
been documented. In this study we make use of the
available monthly PMTCT reports from the launching
of the PMTCT programme in 2004 to August 2009 in
order to examine trends in PMTCT service utilization
and to assess the rate of MTCT in relation to policy
changes.
Methods
A retrospective study was conducted from May to Octo-
ber 2009. PMTCT monthly reports from February 2004
to August 2009 were reviewed in all the 10 sub-cities of
Addis Ababa. The population of Addis Ababa is around
three million, and the city is administratively divided
into 10 sub-cities and 99 Kebeles. In 2007, a total of 30
hospitals, 29 health centres and 442 clinics were provid-
ing health care services [12]. Of the 58 health facilities
offering maternity care services, 81% were providing
PMTCT services. In 2007 alone, over 70,000 pregnant
women who were eligible for PMTCT services were liv-
ing in the city. Over 80% of these pregnant women were
attending antenatal care services, yet only 33.1% of the
deliveries were attended by skilled professionals. Of the
24, 584 pregnant women who received HIV counselling
and testing in 2007, 7.2% were HIV positive [12].
The first national PMTCT guidelines were developed
in 2001 in preparation to launch a PMTCT programme
[4]. In 2004, three years after the development of the
first PMTCT guidelines, a free PMTCT programme was
launched in selected public health facilities [4]. Initially,
only six public health centres were offering PMTCT ser-
vices across the city. The PMTCT programme contin-
ued to expand and from 2007 the programme has been
scaled up to private facilities. As of April 2009, of a total
of 52 facilities offered PMTCT services, 25 of them
being private facilities (unpublished report from Addis
Ababa City Administration Health Bureau). All the
PMTCT facilities were integrated with Antenatal Care
(ANC) service and the majority also provided delivery
services.
For the monitoring and evaluation of HIV prevention
programmes, a M&E system was established in 2003. As
part of the M&E system, the monthly PMTCT reporting
started in February 2004 with Addis Ketema sub-city.
From July 2005, all the sub-cities reported. The PMTCT
reporting format developed by the Ministry of Health
includes output indicators. The format has been distrib-
uted to all service outlets by respective sub-city health
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bureaus. The PMTCT reports were first collected from
the log books at the service outlets and then reported to
the respective sub-cities by the end of each month. In
the sub-cities, the reports from all private and public
facilities were compiled and reported to Addis Ababa
City Administration Health Bureau. In this study we col-
lected the monthly PMTCT reports from the 10 sub-
cities where they compiled data from all service outlets
that started reporting at different times.
The first national PMTCT guidelines was revised in
July 2007 to accommodate changes in policies made by
the WHO from 2004 to 2006 [6]. Until the revised
guidelines came into effect in early 2008, the HIV coun-
selling and testing was offered as an opt-in approach
[13], and sdNVP was given to positive women during
pregnancy and to their infants within 72 hours of birth
[14]. The HIV positive pregnant women were advised to
feed exclusive formula if AFASS; if not, exclusive breast
feeding [15].
According to the revised guidelines, pregnant women
attending ANC should be offered HIV counselling and
testing routinely as an opt-out approach [5,6]. The HIV
positive pregnant women should start ZDV from 28
weeks of gestation plus intrapartum lamivudine and
sdNVP followed by ZDV for seven days postpartum. For
the infant, ZDV and sdNVP should be given at birth fol-
lowed by ZDV for seven days if the mother received
prophylaxis for at least one month, otherwise the infant
should receive ZDV for one month postpartum [1,6,16].
The HIV positive pregnant women should receive infant
feeding counselling in accordance with the 2006 WHO
infant feeding update [6,7]. Moreover, HIV antigen test-
ing of infants with polymerase chain reaction (PCR) at
>= 45 days postpartum replaced the former antibody
testing at >=18 months of age [6]. Nonetheless, early
recommendations on partner testing, irrespective of the
woman’s HIV status, and referring HIV positive preg-
nant women for treatment, care and support remained
unchanged with renewed emphasis in the revised guide-
lines [6].
Data analysis
The reports were entered in Microsoft Excel spreadsheet
and analyzed using Pivotal tables and charts. Prevalence
and Relative risk (RR) were determined and c2 test for
trend was analysed using the Epicalc 2000 software. The
c2 trend tests were used to check whether there was a
linear trend in PMTCT service utilization and HIV pre-
valence across the years and were reported as RR with
associated p-values. The c2 tests for trend change for all
outcome indicators were compared across the years tak-
ing 2004 as the reference time. P-value less than 0.05
was considered significant. Proportions are reported
with 95% confidence intervals.
The following outcome indicators were analysed:
1) The proportion of women who received pre-test
counselling, HIV testing and post-test counselling
among new ANC attendees.
2) The proportion of women who tested positive and
partners who received HIV testing among the total
number of women who tested for HIV.
3) The proportion of women (and babies) who
received ARV prophylaxis, infant feeding counselling
and who were referred for treatment, care and support
among women who tested positive for HIV.
4) The proportion of babies who tested positive
among exposed babies tested for HIV.
Ethical consideration
The study was reviewed and approved by the Regional
Committee for Medical Research Ethics in Western
Norway and the Ethical committee of Addis Ababa
Region Health Bureau in Ethiopia. Study permit from
Addis Ababa Region Health Bureau and respective sub-
cities were obtained.
Results
We obtained 565 PMTCT monthly reports from the 10
sub-cities. In Lideta sub-city three reports were missing
and we collected them from the service outlets instead.
In 6.5% (37) of the reports information on revisiting
ANC attendees was either missing, or new and revisit
attendees were not reported separately.
During February, 2004 to August, 2009, a total of 663
603 pregnant women attended ANC in health facilities
offering PMTCT programme, and 24.6% (163 635) of
them were new attendees. Overall, 135 986 women (new
and revisit ANC attendees) and 4.9% (6 664) of their
partners received HIV testing and 6.2% (8 467) of the
women were HIV positive. Of the tested women, 97.1%
(131 992) received post-test counselling. Among the
HIV positive women, 42.4% (3 594) received ARV pro-
phylaxis, 41.0% (3 474) were referred for treatment, care
and support and 82.8% (7 010) received infant feeding
counselling. Among babies born to the HIV positive
women, 31.0% (2 621) received ARV prophylaxis and
10.6% (896) were tested for HIV (See Additional file 1:
Compiled data from February, 2004 to August, 2009
from the 10 sub-cities).
Trends in HIV counselling and testing
Fig 1 presents the year by year trend in HIV counselling
and testing utilization. The proportion of women who
received pre-test counselling, testing and post-test coun-
selling among new ANC attendees was 66.3% (95% CI
64.8-67.7) in 2004 based on the reports from the three
sub-cities that started reporting in 2004. In 2005, following
the PMTCT programme scale up to the rest of the
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sub-cities, the counselling and testing utilization dropped
to 32.1% (95% CI 31.5-32.7). Although the drop appeared
to be marked in the three sub-cities that started reporting
earlier, those that started later also showed a similar trend.
The poor utilization persisted till 2007 when only 50.7%
(95% CI 50.2-51.2) of the new attendees received HIV
counselling and testing. The PMTCT programme gained
momentum in 2008 when the revised guidelines that
incorporated routine opt-out testing offer came into effect.
Utilization of HIV counselling and testing increased to
84.5% (CI 84.1-84.9) in 2009. The trend in receiving post-
test counselling remained stable at high level across the
years which imply that almost all the tested women col-
lected their HIV test result (Fig 1).
There were variations across the sub-cities in the pro-
portion of women who had not received pre-test coun-
selling or testing. In 2009, one year following the shift
to routine opt-out approach, 12.0%, 18.4%, 19.3%, 14.0%,
14.6% and 27.3% of the women attending ANC in Addis
Ketema, Arada, Bole, Kirkos, Lideta and Nifas Silk Lafto
sub-city, respectively, did not receive pre-test counsel-
ling. Similarly, among women who received pre-test
counselling in 2009, 17.3%, 11.3%, 17.0% and 24.8% in
Arada, Bole, Gulele and Kirkos sub-cities, respectively,
did not receive HIV testing.
HIV testing versus HIV prevalence
Fig 2 presents the overall trends in HIV prevalence
among ANC attendees across the years. The HIV preva-
lence among the total ANC attendees (both new and
revisit) who tested for HIV appeared to decline steadily
from 10.5% (CI 9.6 -11.5) in 2004 to 4.6% (95% CI 4.3 -
4.8) in 2009 (RR 0.46) in parallel with the increasing
number of women testing for HIV. During the same
period the trends in HIV prevalence across the sub-
cities showed significant decline, except Yeka sub-city
where the HIV prevalence actually increased by 17% in
2009 compared to 2004 (RR 1.17, p < 0.05) (Table 1).
ARV Prophylaxis uptake
Of the 8 467 HIV positive women, ARV prophylaxis was
given to 42.4% (95% CI 41.4-43.5) and to 31.0% (95% CI
30.0-31.0) of their infants. From early 2008, the prophy-
laxis regimen was shifted from sdNVP to multidrug ZDV
regimen. Despite the big difference in the two regimens,
the reports did not show marked changes of the trend in
prophylactic ARV uptake. In 2004, the ARV prophylaxis
uptake by the women and infants was low, but the gap in
prophylaxis uptake between the women (24.8%. 95% CI
20.8-29.2) and babies (23.2%. 95% CI 19.3-27.5) was nar-
row. In 2005 and 2006 an increased proportion of
women received prophylaxis, 41.6% (95% CI 39.0-44.3)
and 55.0% (95% CI 52.3-57.4) respectively. In 2006 the
proportion and number of women who received ARV
prophylaxis peaked, yet only 35.1% (95% CI 32.8-37.4) of
their infants received prophylaxis, resulting in the widest
gap in prophylaxis uptake. In 2007, the prophylaxis
uptake by the women and infants dropped to 33.8% (95%
CI 31.6-36.1) and 25.4% (95% CI 23.4-27.5), respectively,
and the gap narrowed again. The prophylaxis uptake
shows an increasing trend since 2008 (Fig 3).
Figure 1 Proportion of women who received pre-test counselling, testing and post-test counselling among new ANC attendees. — In
2004 to 2007 when the HIV testing was offered in an opt-in approach. ___In 2008 and 2009 when the HIV testing was offered routinely in an
opt-out approach.
Figure 2 Trends in HIV prevalence among antenatal care
attendees tested in PMTCT settings from 2004 to 2009 in
Addis Ababa.
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Referral for treatment, care and support
The need for referring HIV positive pregnant women for
treatment, care and support gained momentum in
response to the 2004-2006 national roadmap to acceler-
ate access to antiretroviral therapy [17] and the launch-
ing of the revised PMTCT guidelines [6]. The
proportion of HIV positive pregnant women referred for
treatment, care and support increased from 3.2% (95%
CI 1.9-5.5) in 2004 to 59.9% (95% CI 57.2-62.5) in 2009.
In other words, the HIV positive pregnant women in
2009 were over 18 times more likely to be referred for
treatment, care and support than their counterparts in
2004 (RR 18.5 X2 trend p < 0.0001).
Infant feeding counselling
In 2004, when the PMTCT programme was first
launched, 58.3% (95% CI 53.5-63.0) of the HIV positive
women received infant feeding counselling, compared to
87.3% (95% CI 85.3-89.0) in 2009. The HIV positive
women in 2009 had a 50% more chance to receive
infant feeding counselling than the positive women in
2004 (RR 1.5, c2 trend p < 0.001). Despite the changes
in infant feeding recommendation at different times, the
report lack information on the kind of infant feeding
advice given, infant feeding choice made by the women
or pattern of infant feeding.
HIV infection among exposed babies
Overall, only 10.6% (896) (95% CI 9.9-11.2) of the HIV
positive women completed their follow up to child HIV
testing. The rate of MTCT was evaluated based on the
896 babies tested for HIV during the period 2006-2009.
Among the 896 exposed babies 106 were HIV positive.
Of the babies on sdNVP regimen who tested at >=18
months with rapid antibody test, 14.3% (95% CI 7.92-
24.0) in 2006 and 15.0% (95% CI 9.8-22.1) in 2007 were
HIV positive. In 2009, among babies on the multidrug
ZDV regimen who tested at >=45 days postpartum with
Table 1 HIV prevalence among antenatal care attendees who tested for HIV, relative risk and c2 for trend test across
the years by sub-city
Sub-city 2004 2005 2006 2007 2008 2009 c2 trend
% (n) RR % (n) RR % (n) RR % (n) RR % (n) RR % (n) RR
Addis Ketema 12.8(195) Ref 11.1(168) 0.99 7.4(170) 0.66 7.8(231) 0.70 4.6(178) 0.41 4.7(130) 0.42 127.3 *
Akaki Kaliti 8.7(99) Ref 7.0(131) 0.81 6.8(16) 0.78 4.9(136) 0.57 5.3(113) 0.61 22.3 *
Arada 8.9(134) Ref 8.2(185) 0.92 6.3(159) 0.71 5.9(298) 0.66 3.8(123) 0.43 64.4 *
Bole 8.6(89) Ref 10.0(112) 1.17 6.8(149) 0.79 5.5(158) 0.64 4.8(171) 0.56 3.2(130) 0.37 105.4*
Gulele 6.7(77) Ref 6.6(118) 0.98 5.7(156) 0.84 5.0(136) 0.75 4.5(93) 0.67 12.1**
Kirkos 10.2(89) Ref 9.5(188) 0.93 7.1(162) 0.69 6.8(191) 0.66 4.6(122) 0.44 54.3 *
Kolfe Keraniyo 5.4(67) Ref 4.9(75) 0.91 2.8(70) 0.51 3.3(73) 0.62 3.7(81) 0.69 7.7‡
Lideta 9.6(148) Ref 10.2(244) 1.06 6.8(198) 0.71 5.9(228) 0.62 4.8(246) 0.50 4.6(217) 0.48 119.8*
Nifas-silk Lafto 8.0(175) Ref 7.5(253) 0.93 6.0(232) 0.74 4.6(217) 0.57 4.0(140) 0.49 70.5*
Yeka 7.9(161) Ref 7.6(228) 0.96 8.2(206) 1.03 9.3(268) 1.17 9.2(193) 1.17 6.2‡
Ref = Reference *P < 0.0001 **P < 0,001 ‡P < 0,01 ‡ ‡ P < 0,05 NB: The denominator for each cell is different
Figure 3 Percentage of women and babies who received ARV prophylaxis from 2004 to 2009 in Addis Ababa.
Mirkuzie et al. BMC Health Services Research 2010, 10:267
http://www.biomedcentral.com/1472-6963/10/267
Page 5 of 10
antigen test using PCR, 8.2% (95% CI 5.55-11.97) were
HIV positive (Fig 4).
Partner testing
The overall trend in the proportion of partners tested
among women who received HIV testing remained stable
at low level i.e 6.4% (95% CI 5.7-7.2) in 2004 and 5.3%
(95% CI 5.0-5.5) in 2009. Compared to the women who
were tested in 2004, women tested in 2009 were 14% less
likely to be tested with their partner (RR 0.86, p < 0.01).
However, there was an increase in the absolute number
of partners tested across the years in parallel with the
increased number of women who tested positive. In 2009
the number of partners tested was higher than the num-
ber of women who tested positive (Fig 5).
Discussion
In this study we examined trends in PMTCT service uti-
lization and assessed the rate of MTCT in Addis Ababa,
Ethiopia. The HIV counselling and testing service utili-
zation improved substantially in 2009 following policy
shift to routine opt-out approach. The HIV prevalence
appeared to decrease steadily paralleling the increased
number of women tested for HIV. Irrespective of policy
changes, the uptake of ARV prophylaxis and loss to fol-
low up remained unimproved. Out of the 10.6% (896)
exposed babies tested for HIV, the cumulative probabil-
ity of HIV infection decreased to 15.0% by 2007 among
babies on sdNVP regimen tested at >=18 months of age,
and to 8.2% by 2009 among infants on ZDV regimen
tested at >=45 days of age. The proportion of HIV posi-
tive pregnant women referred for treatment, care and
support increased eighteen-fold in 2009 compared to
2004. Meanwhile, the proportion of partners tested in
the PMTCT setting declined significantly by 14% from
2004 to 2009.
The proportion of women who received HIV counsel-
ling and testing among new ANC attendees increased
significantly from 50.7% in 2007 to 84.5% in 2009 fol-
lowing the shift to routine opt-out testing. Consistent
with our findings, studies from other resource poor set-
tings have revealed significant improvement in HIV test-
ing at ANC from 45% to 99% following the shift to
routine opt-out approach [18-20]. Nevertheless, over
10% of the new ANC attendees had not received pre-
test counselling or testing in 2009. In this regard the
opt-out approach, which seems to be robust to maxi-
mise HIV testing in many settings [18-20], did not show
remarkable success in our study. This could be attribu-
ted to two major reasons. First, most of the studies that
reported nearly a 100% HIV test acceptance when test-
ing was offered routinely as an opt-out approach, were
pilot initiatives [18-20], unlike our study that compiled
Figure 4 HIV infection among exposed babies tested for HIV
from 2006 to 2009 in Addis Ababa.
Figure 5 Trends in partner testing in the PMTCT settings from 2004 to 2009 in Addis Ababa.
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PMTCT reports from a national programme. In line
with our argument, a study in Kenya based on data
from 43 PMTCT service outlets reported a 80.6% HIV
test acceptance [21]. Second, the expansion of the
PMTCT programme to private facilities seem to have
contributed to the persistence of a large proportion of
women who had not received HIV counselling or testing
even after the shift to routine testing. Site factors are
reported to be more relevant than participant factors in
determining HIV test acceptance in a study from Kenya
[21]. In particular, characteristics of the provider appear
to be an important determinant for HIV test acceptance.
For instance, characteristics of the midwives were found
to be an independent determinant for HIV testing
uptake in England [22], whereas high test refusal was
associated with HIV testing being offered by general
practitioners in Canada [21,23]. In almost all the private
facilities in Addis Ababa, ANC and HIV testing was
offered by physicians who had little or no training on
HIV counselling and testing in an opt-in approach. This
indicates that there are gaps in the implementation of
the routine opt-out testing strategy, particularly in pri-
vate facilities. On top of that, the utilization of post-test
counselling and collection of test result by almost all
tested women throughout the years, irrespective of the
testing approach employed, implies that the persistent
gap in pre-test counselling and HIV testing service utili-
zation could be an evidence of failure of the health sys-
tem to deliver the programme rather than a failure of
the women.
The HIV prevalence among the tested women had
reduced by 54% in 2009 compared to the level in 2004, in
parallel to the increased number of women being tested.
Similar declining trend in HIV prevalence has been
observed among adults and from a sentinel surveillance
report in Ethiopia. Synergy between the natural progres-
sion of the HIV epidemic and behaviour changes among
the general population in terms of increased condom use
and reduced risky sexual behaviour seem to contribute to
the declining prevalence [3,4]. The HIV prevalence esti-
mate in our study was lower than that of the ANC senti-
nel surveillance report, i.e 6.2% vs 9.3% in 2007/2008
[12]. Consistent with our finding, a study that compiled
data from Kenya, Ethiopia, and Zimbabwe for 2005
reported that the HIV prevalence in Ethiopia was 6.4%
from PMTCT programme reports and 8.2% from sentinel
surveillance reports [24-26]. The two reports, although
generated from the same population, have differences in
population size and timing of data collection [24-26].
The PMTCT report includes all women who participated
in the PMTCT programme all year round. In the sentinel
surveillance, leftover blood samples were collected from
a smaller number of ANC attendees from selected facil-
ities, often for a period of 3 months biennially.
The decreasing trend in the HIV prevalence estimate
across the years could also be attributed to a more
representative sample of pregnant women tested for
HIV in our study. In other words, the inclusion of more
service outlets and therefore reaching out to a large
population in our study seems to be more representa-
tive, unlike the sentinel surveillance report that relied
on reports from a few public facilities. Even in the senti-
nel surveillance reports, as the number of sentinel sites
increased the estimated HIV prevalence declined [4].
More importantly we included reports from private
facilities where the HIV prevalence is reported to be
lower compared to ANC attendees in public facilities,
2.4% (unpublished report from Addis Ababa City
Administration Health Bureau) vs 9.3% [12] respectively
in 2007/2008. Moreover, the HIV prevention potential
of Highly Active Antiretroviral Therapy (HAART)
should not be ignored [27].
Despite the marked increase in HIV testing following
the shift to routine opt-out approach, neither the pro-
portion nor the number of women receiving ARV pro-
phylaxis have increased. In 2009, only 53.7% of the
women and 40.7% of their babies received ARV prophy-
laxis. Consistent with our findings, in Addis Ababa,
49.3% of the HIV positive women and 35.3% of their
babies received ARV prophylaxis in 2007/2008 [28] and
the programme achieved only 30% compared to 80% as
the target [12]. Actually, poor ARV prophylaxis uptake
is not a new story, even those intervention studies that
show almost 100% successes in HIV testing were in
short of ARV prophylaxis uptake [18-20]. However, the
lack of improvement in ARV prophylaxis utilization fol-
lowing the shift to routine testing is an issue of great
concern as the shift to an opt-out approach was primar-
ily intended to increase the proportion of women and
infants receiving prophylactic ARV drugs [5]. In the era
of routine testing for HIV, the PMTCT programme
appears to be an effective screening programme than a
prevention programme due to the large number of
dropouts after testing. Yet, the gain in HIV testing turn-
out limits the weakness of the routine opt-out approach
in terms of subsequent dropouts and poor adherence to
ARV prophylaxis [29]. Currently the availability of
potent ARV prophylaxis is changing the landscape, and
even mother-to-child HIV transmission through breast
feeding has become less of a concern [30]. Yet, still
more lives are at stake because of the lack of improve-
ment in uptake of this critical component of the
PMTCT programme.
According to Kasenga et al., skilled attendance at birth
is an important determinant of ARV prophylaxis uptake
that requires thorough consideration [31]. In Addis
Ababa, only 30% of the pregnant women had skilled
attendance at birth in 2008 [12] corresponding to the
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proportion of infants who received ARV prophylaxis
[28]. Since infants are given prophylaxis within 72 hours
of birth at the health facility, infants delivered at home
have less chance to receive ARV prophylaxis than
infants delivered in health facilities. An intervention
study from Zambia gives some hope that dropouts and
non-adherence to ARV prophylaxis could be reduced to
zero. This study, which employed multiple interventions,
increased the ARV prophylaxis uptake from 29% at
baseline to 100% within 3 years [32]. This gives reassur-
ance that the official 80% ARV prophylaxis uptake goal
for Ethiopia could be achieved through concerted effort
and renewed commitment.
According to the findings, an increasing proportion of
HIV-positive pregnant women were referred for treat-
ment, care and support services, from 3.2% in 2004 to
59.9% in 2009. The referral is intended for prompt
initiation of ARV prophylaxis or treatment for eligible
women using CD4 or lymphocyte count and WHO sta-
ging criteria [6]. By doing so, the programme is addres-
sing the most important issues that PMTCT
programmes have been criticized for, i.e the lack of sen-
sitivity to the needs of pregnant women. The PMTCT
programme is increasingly successful in bridging the gap
between prevention and treatment to address the moral
and ethical questions raised over the years [1]. The eigh-
teen-fold increase in the proportion of positive pregnant
women being referred for treatment, care and support
from 2004 to 2009 demonstrates the good will and the
potential to integrate new policies and strategies. Yet,
more has to be done to ensure that all HIV-positive
pregnant women have access to prophylaxis or treat-
ment, care and support.
The ultimate objective of a PMTCT programme is to
avert new HIV infections among children. However,
only 10.6% (896) of the HIV positive pregnant women
completed their follow up to infant HIV testing. The
rates of MTCT were therefore assessed based on test
result of the 896 babies tested for HIV. In the absence
of any PMTCT intervention the cumulative probability
of HIV infection among exposed babies aged >=18
months is in the range of 29% to 47% according to a
cohort study conducted in an orphanage in Addis
Ababa [4]. In our study, the cumulative probability of
HIV infection among exposed babies on sdNVP regimen
tested at >=18 months was 14.3% in 2006 and 14.9% in
2007. According to the HIVNET 012 randomized trial,
sdNVP regimen has a 41% efficacy. In this trial, consis-
tent with our findings, the cumulative probability of
infant HIV infection is 15.7% among breast fed infants
tested at >=18 months [14]. However, a methodologi-
cally similar study from Malawi that compiled monthly
reports showed a 15.5% HIV infection rate among
infants on sdNVP regimen tested at 6 weeks postpartum
without accounting for the breast feeding transmission
[33]. Nevertheless, there is a possibility that our estimate
could be biased due to the large loss to follow up.
In 2009, 8.2% of the exposed infants on ZDV regimen
tested at 45 days were HIV positive. In the Petra clinical
trial, multidrug ZDV regimen showed 63% efficacy in
reducing MTCT. In this trial the rate of HIV transmis-
sion among infants on multidrug ZDV regimen tested at
45 days was 5.7% [16]. Considering the fact that our
data are generated from a national PMTCT programme
and the obvious methodological difference with the
Petra trial, the 8.2% infant infection rate reported in our
study indicates the success of the national PMTCT pro-
gramme among those who completed their follow up to
infant HIV testing. A cohort study from similar resource
poor settings that evaluated the effectiveness of a
PMTCT programme among predominantly formula fed
infants on ZDV regimen tested at >=45 days reported a
9.1% cumulative infant HIV infection, higher than the
rate of HIV infection reported in our study [34]. How-
ever, since the HIV testing was done at >=45 days,
those HIV negative infants who continue to breast feed
are still at risk of acquiring new infection. In general,
the rate of MTCT averted by the national PMTCT pro-
gramme appears promising among those who adhered
to the programme. Nevertheless, the possibility of
underestimation cannot be excluded since we lack infor-
mation on loss to follow up. In line with this limitation,
Ahoua et al. found that the cumulative probability of
infant HIV infection among tested infants was 8.3%,
whereas it was 15.5% when HIV related deaths were
included in the analysis [35].
The last, but not least important PMTCT programme
outcome indicator examined in our study was partner
testing. The proportion of partners tested remained very
low with a 14% significant decline in 2009 compared to
2004. A review on couple centred counselling shows
that partner involvement in HIV testing not only helps
to increase disclosure, condom use and uptake of ARV
prophylaxis but also contributes to the lower rate of ser-
oconversion compared to individual counselling [8]. We
noted a parallel trend in the number of partners tested
with the number of women who tested positive across
the years. This indicates that most of the partners who
came for HIV testing were those whose wives tested
positive. Partner testing in the context of PMTCT
seems to facilitate women’s coping, yet missing out the
important prevention aspect by not advising HIV nega-
tive women to bring their partner for testing.
A study from South Africa shows that 3% of the preg-
nant women who were found to be HIV negative in
their first HIV testing during pregnancy became HIV
positive in repeat test in late pregnancy, giving a 10.7%
incidence per year [36]. This indicates that women are
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at risk to acquire new HIV infection from their HIV
positive partner anytime during pregnancy and even
during breast feeding. In eastern and southern African
region, including Ethiopia, 36-85% of HIV positive indi-
viduals are believed to live with an HIV negative partner
[4,10]. Discordant couples are the newly identified high
risk group in Ethiopia, as most infections are occurring
within marriage. Because of mucosal and hormonal
changes during pregnancy, the HIV incidence is four
times higher among pregnant women compared to their
non-pregnant counterparts [37]. Meanwhile, women
having recent HIV infection are more likely to transmit
HIV infection to their babies [36]. Therefore, it is crucial
to focus on partner testing and involvement in the
PMTCT programme to optimise programme effective-
ness. The current strategies in Addis Ababa, that include
giving priority for women coming with their partner for
testing and sending an invitation home to partner
should be encouraged.
One of the limitations of our study is that the rate of
MTCT was examined based on infants tested for HIV,
which could actually be underestimated due to the large
loss to follow up. Considering the lack of a system to
trace loss to follow up, our finding still highlights the
potentially averted infections. Another limitation is that
the PMTCT programme reached out to only 80% of
pregnant women due to incomplete ANC attendance
[12] and the findings seem not to represent the whole
nation, where a high proportion of the population is
rural. However, since it was generated from a national
programme, lessons learnt herein could benefit the
PMTCT programme across the country. We also believe
that our findings are generalisable to the big cities
where the HIV prevalence is higher.
Retrospective data collected primarily for reporting
purposes always have weakness, especially in resource
poor settings where the quality of reports are often
questionable [11]. By limiting our study objectives to
those indicators that could be calculated from the
reports we minimized the risk of having incomplete
data. We obtained almost all the reports from February
2004 to August 2009 from the 10 sub-cities. To validate
our data we checked Addis Ababa City Administration
Health Bureau and NGO reports, and our data were
found to be consistent. For missing reports we obtained
data from log books and reports at service outlets.
Conclusion
Our findings suggest that the proportion of women
receiving HIV counselling and testing has increased sub-
stantially from 2004 to 2009. The shift in HIV testing
approach has further reduced the proportion of women
not receiving HIV counselling and testing. However, the
lack of improvement in ARV prophylaxis uptake after the
shift to routine opt-out testing is an issue of great con-
cern as the shift was intended to facilitate access to ARV
prophylaxis. The health system appeared not only to fail
to deliver the most critical component of the PMTCT
programme, i.e ARV prophylaxis, but also to retain the
HIV positive women to complete their follow up. The
effectiveness of the national PMTCT programme is ques-
tionable as only 10% of the HIV positive women com-
pleted their follow up to infant HIV testing. A tracing
system for loss to follow up should be in place for mea-
suring the actual impact of the programme. In addition,
the sub-cities and the Addis Ababa city Administration
Health Bureau must devise a mechanism to increase pro-
phylaxis uptake and to retain the HIV positive women in
the programme until the follow up is completed. The
counselling Training should emphasize partner testing to
ensure that all women tested in PMTCT settings receive
counselling on partner testing, irrespective of their HIV
status. Further research is imperative to identify and
address challenges to ARV prophylaxis uptake, partner
testing, referral for treatment, care and support and chal-
lenges to follow up. We recommend the health facilities,
sub-cities and the City Administration Health Bureaus to
utilize the monthly reports to identify gaps in service uti-
lization and to come up with context specific solutions
for the realisation of the country’s goal of “HIV free
generation by 2020”.
Additional material
Additional file 1: Compiled monthly PMTCT reports from February,
2004 to August, 2009 for the 10 Sub-cities in Addis Ababa. The
table containes monthly PMTCT reports from February, 2004 to August
2009 collected from the 10 sub-cities. Addis Ketema, Bole and Lideta
sub-cities started reporting from 2004 while the rest of the sub-cities
reported from 2005.
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